1. Home
  2. CDLR vs SRPT Comparison

CDLR vs SRPT Comparison

Compare CDLR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

N/A

Current Price

$6.67

Market Cap

2.1B

Sector

N/A

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

N/A

Current Price

$17.67

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDLR
SRPT
Founded
2008
1980
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
CDLR
SRPT
Price
$6.67
$17.67
Analyst Decision
Hold
Analyst Count
0
24
Target Price
N/A
★ $21.64
AVG Volume (30 Days)
97.6K
★ 2.5M
Earning Date
11-23-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 2.78
Revenue
N/A
★ $2,198,237,000.00
Revenue This Year
$57.98
N/A
Revenue Next Year
$37.55
N/A
P/E Ratio
$7.39
★ $6.83
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$14.68
52 Week High
$32.81
$24.68

Technical Indicators

Market Signals
Indicator
CDLR
SRPT
Relative Strength Index (RSI) 18.71 45.22
Support Level N/A $16.51
Resistance Level $25.23 $18.45
Average True Range (ATR) 1.82 0.99
MACD -1.76 -0.01
Stochastic Oscillator 0.42 21.06

Price Performance

Historical Comparison
CDLR
SRPT

About CDLR Cadeler AS

Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: